Log in

RMD RESMED INC NYSE · United States

RESMED INC (RMD) news

RESMED INC is a public biotech or pharmaceutical company listed on NYSE under the ticker RMD, recorded under United States. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Latest RESMED INC news

We have not published a story on RESMED INC yet. When there is news, it will appear here.

What RESMED INC does

ResMed is a global digital health company that designs AI-powered, cloud-connected medical devices and software to improve home healthcare. It began in 1989 with CPAP treatment for obstructive sleep apnea, the first successful non-invasive treatment for that condition, and it now offers diagnostic products, masks, ventilation devices and connected care software. In June 2026 it acquired Noctrix Health, which makes an FDA De Novo classified device for restless legs syndrome. In 2025 it acquired VirtuOx, a software-enabled independent diagnostic testing facility for in-home sleep and respiratory testing. ResMed operates two segments, Sleep and Breathing Health and Residential Care Software. Its software businesses include Brightree for durable medical equipment providers and MEDIFOX DAN for residential care in Germany. On June 30, 2026, it agreed to sell its MatrixCare business for $490 million in cash. The company says it employs approximately 11,370 people and sells in more than 140 countries.

Product or programWhat it isStage
CPAP systemsTreatment for obstructive sleep apnea
Noctrix Health deviceFDA De Novo classified device for restless legs syndromeacquired June 2026
MatrixCareCare management software for senior living, skilled nursing and home healthsale agreed for $490 million
BrightreeSoftware for durable or home medical equipment providers
MEDIFOX DANCare management software for residential care providers in Germany

Summarised from the company's 10-K filed Aug 13, 2026.

RESMED INC annual financials

LineFY ended Jun 30, 2026FY ended Jun 30, 2025
Research and development$378.3 million$331.3 million
Net income (loss)$1.52 billion$1.40 billion
Cash from operations$1.81 billion$1.75 billion
Cash and equivalents$1.47 billion$1.21 billion

Latest balance sheet, Sep 30, 2026 (10-Q): cash and equivalents $1.01 billion.

Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice.

Questions about RESMED INC

What is the ticker symbol of RESMED INC?

RESMED INC trades under the ticker RMD on NYSE.

Where is RESMED INC listed?

RESMED INC is listed on NYSE.

Which country or territory is RESMED INC listed under?

Our directory records RESMED INC under United States.

Does aibio.space cover RESMED INC?

aibio.space lists RESMED INC among 2,820 public biotech companies and publishes its news here as stories appear.

What does RESMED INC develop?

ResMed is a global digital health company that designs AI-powered, cloud-connected medical devices and software to improve home healthcare. It began in 1989 with CPAP treatment for obstructive sleep apnea, the first successful non-invasive treatment for that condition, and it now offers diagnostic products, masks, ventilation devices and connected care software.

What is CPAP systems from RESMED INC?

CPAP systems: Treatment for obstructive sleep apnea

What is Noctrix Health device from RESMED INC?

Noctrix Health device: FDA De Novo classified device for restless legs syndrome Stage: acquired June 2026.

Is RESMED INC profitable?

RESMED INC reported net income of $1.52 billion for the fiscal year ended Jun 30, 2026, and generated $1.81 billion of cash from operations, per its annual report to the SEC.

How much does RESMED INC spend on research and development?

$378.3 million in the fiscal year ended Jun 30, 2026, per its annual report.

How much cash does RESMED INC have?

$1.01 billion in cash at Sep 30, 2026, per its 10-Q.

Investor discussion: RESMED INC

Members talk about RESMED INC (RMD). Reader posts, not aibio.space reporting, and not investment advice.

Rules
  1. Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
  2. Say whether you hold the stock. Every post states long, short or no position.
  3. No paid or sponsored posts. Do not post for anyone who pays or rewards you.
  4. No buy or sell calls and no price targets.
  5. No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
  6. No personal details and no spam. No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.

Capital-markets timeline

Financings, listing notices, splits, legal actions and other investor events at RESMED INC, newest first. Each line links the filing it comes from.

  1. Legal

    Reported a change of independent auditor. SEC Form 8-K (Items 4.01,5.02,7.01,9.01). Source

Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open NYSE:RMD on TradingView.

Listing details

RESMED INC is a public biotech or pharmaceutical company listed on NYSE under the ticker RMD, recorded under United States. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Company
RESMED INC
Ticker
RMD
Listing
NYSE
Country or territory
United States

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.

Published and maintained by aibio.space. Not investment advice. How we work.

Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction

Full desks

Every other company has a starter desk. Search above to open one.

Settings

Appearance
Text size
Motion

Stops the news strip and the share rollers.

Your choices are saved in this browser only.

Free membership

Read aibio.space in full, free

Subscribe with your email address to read every story, company desk and profile in full. It costs nothing. In return, you agree that we may email you, including offers. One click to unsubscribe.

No card, no password. With email, we send one message to confirm your address first. With Google or Facebook we receive only your email address. Not investment advice.